Tweets
Cool study investigating differences in nailfold capillaroscopy, jives w/my clinical experience
Compared to SLE, pts with DM 🔼nailfold changes, 🔼 loop dilation, 🔼hemorrhages
#ACR24 @rheumnow Abstr#2404 https://t.co/8N7KNRZet8
Mike Putman @EBRheum ( View Tweet )
1 year 5 months ago
Dr. @karen_kc123 discusses the results of the VITAL study.
- Long term use of Vit D3 2000IU was safe and decreased the incidence of all autoimmune dses by 22%.
- It took a while to work but the effect dissipates once discontinued.
@RheumNow #ACR24
@rheumarhyme https://t.co/mnwRsdZ06N
Links:
sheila @RHEUMarampa ( View Tweet )
1 year 5 months ago
Will be covering some TAK pearls and pitfalls from today’s session!
Renal dz stratified by location of vessel inflammation:
- TAK = proximal (off aorta)
- FMD = mid-section, beading
- PAN = distal arterial branches
@RheumNow #ACR24 https://t.co/zu6qJ6DXcF
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
1 year 5 months ago
A call for ANA stewardship?
Abstract 1931: Educating clinicians on wise ANA ordering via EMR Alert plus removing the comprehensive ANA panel -->
- ↓ ANA testing (outpatient 15.9%→7.4%, inpatient 25.5%→6.4%)
↓ costs ($440k→$130k)
#ACR24 @RheumNow
Akhil Sood MD @AkhilSoodMD ( View Tweet )
1 year 5 months ago
Study of 25K+ patients using TrinetX on immune checkpoint inhibitors shows no significant mortality difference between those with pre-existing autoimmune disease (AID) and those without.
Mortality rates:
AID: 39.8%
Non-AID: 40.2%
Large-scale evidence supports ICIs in AID… https://t.co/BI5jK9jsoM
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 5 months ago
A#2531 @AlisaMueller
CRISPR deletion of fibroblasts, gave cytokine activation to mimic inflamm
Are there gene depletions that affect inflamm pathways?
👉SIX1 reduces inflamm potentiation
👉NFIL3 deletion promotes inflamm, degradation
@RheumNow #ACR24 https://t.co/Nqghb5UaBR
Links:
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
A#2532
Pre-existing AID for immunoRx?
Excluded from trials
4 prior studies showed no diff in mortality w AID
Propensity-matched cohort study
Followed median 250 days
Hazard ratio: 1.07 (unmatched), 0.97 (matched) - no diff. Mortality about 40% in grps
@RheumNow #ACR24 https://t.co/zyVCPts6s6
Links:
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
#ACR24 Guidelines #LupusNephritis for refractory dz @RheumNow https://t.co/LlSixkggKK
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 5 months ago
Imaging in TAK Diagnosis
@KQuinnRheum @RheumNow
⭐ Take homes ⭐
👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK
👉FDG PET -focal uptake in TAK vs diffuse in GCA
👉MRI good surrogate for disease activity where PET unavailable
#ACR24 https://t.co/UWxTAZScIt
Links:
Patricia Harkins @DrTrishHarkins ( View Tweet )
1 year 5 months ago
Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA).
Key findings:
- 21.7% of patients required ≥4 biologic/targeted synthetic DMARDs.
- Female patients and those with depression were more likely to be recalcitrant.
- No… https://t.co/I9YYoRnLwh https://t.co/VtnPceVLOZ
Links:
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 5 months ago
#ACR24 - Featured Industry Presentations
Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.… https://t.co/I6LMQ5xMUx https://t.co/UzTeqWUSdo
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
The precise mechanism of action of GIOP is not known. Decrease in osteocyte LCN is observed. Abstr#2528 @RheumNow #ACR24 https://t.co/fazUUy03fQ
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 5 months ago
